Structure Therapeutics (GPCR) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
UroGen Pharma (URGN) has outperformed Structure Therapeutics (GPCR) over the past year, gaining 113.4% versus a loss of 9.8%. Structure Therapeutics is the larger company by market cap ($1.85 billion vs $1.82 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | URGN |
|---|---|---|
| Share price | $25.90 | $37.16 |
| Market cap | $1.85B | $1.82B |
| 1-day change | +0.90% | +0.49% |
| YTD return | -63.09% | +57.90% |
| 1-year return | -9.77% | +113.39% |
| 5-year return | — | +117.27% |
| Forward P/E | — | 13.30 |
| EPS (TTM) | $-3.03 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $109.79M |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | $-141.20M | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | — | -113.73% |
| Net margin | — | -139.81% |
| 52-week high | $94.90 | $50.81 |
| 52-week low | $25.09 | $15.86 |
| Distance from 52-week high | -72.71% | -26.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +308.42% | +61.46% |
| Average volume | 965.00K | 849.01K |
| Shares outstanding | 71.31M | 48.88M |
| Employees | 281 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed GPCR by 123.2 percentage points over the past year.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
GPCR vs URGN FAQ
Which is bigger, Structure Therapeutics or UroGen Pharma?
Structure Therapeutics (GPCR) is larger, with a market capitalization of $1.85B compared with $1.82B for UroGen Pharma (URGN).
Which stock has performed better over the past year, GPCR or URGN?
URGN returned +113.39% over the past 12 months, compared with -9.77% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.